Cargando…

In-hospital costs of community-acquired colonization with multidrug-resistant organisms at a German teaching hospital

BACKGROUND: Antibiotic resistance is a challenge in the management of infectious diseases and can cause substantial cost. Even without the onset of infection, measures must be taken, as patients colonized with multi-drug resistant (MDR) pathogens may transmit the pathogen. We aim to quantify the cos...

Descripción completa

Detalles Bibliográficos
Autores principales: Engler-Hüsch, Sabine, Heister, Thomas, Mutters, Nico T, Wolff, Jan, Kaier, Klaus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158851/
https://www.ncbi.nlm.nih.gov/pubmed/30257671
http://dx.doi.org/10.1186/s12913-018-3549-0
_version_ 1783358499071197184
author Engler-Hüsch, Sabine
Heister, Thomas
Mutters, Nico T
Wolff, Jan
Kaier, Klaus
author_facet Engler-Hüsch, Sabine
Heister, Thomas
Mutters, Nico T
Wolff, Jan
Kaier, Klaus
author_sort Engler-Hüsch, Sabine
collection PubMed
description BACKGROUND: Antibiotic resistance is a challenge in the management of infectious diseases and can cause substantial cost. Even without the onset of infection, measures must be taken, as patients colonized with multi-drug resistant (MDR) pathogens may transmit the pathogen. We aim to quantify the cost of community-acquired MDR colonizations using routine data from a German teaching hospital. METHODS: All 2006 cases of documented MDR colonization at hospital admission recorded from 2011 to 2014 are matched to 7917 unexposed controls with the same primary diagnosis. Cases with an onset MDR infection are excluded from the analysis. Routine data on costs per case is analysed for three groups of MDR bacteria: Methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococcus (VRE), and multidrug-resistant gram-negative bacteria (MDR-GN). Multivariate analyses are conducted to adjust for potential confounders. RESULTS: After controlling for main diagnosis group, age, sex, and Charlson Comorbidity Index, MDR colonization is associated with substantial additional costs from the healthcare perspective (€1480.9, 95%CI €1286.4–€1675.5). Heterogeneity between pathogens remains. Colonization with MDR-GN leads to the largest cost increase (€1966.0, 95%CI €1634.6–€2297.4), followed by MRSA with €1651.3 (95%CI €1279.1–€2023.6), and VRE with €879.2 (95%CI €604.1–€1154.2). At the same time, MDR-GN is associated with additional reimbursements of €887.8 (95%CI €722.1–€1053.6), i.e. costs associated with MDR-colonization exceed reimbursement. CONCLUSIONS: Even without the onset of invasive infection, documented MDR-colonization at hospital admission is associated with increased hospital costs, which are not fully covered within the German DRG-based hospital payment system. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12913-018-3549-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6158851
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-61588512018-10-01 In-hospital costs of community-acquired colonization with multidrug-resistant organisms at a German teaching hospital Engler-Hüsch, Sabine Heister, Thomas Mutters, Nico T Wolff, Jan Kaier, Klaus BMC Health Serv Res Research Article BACKGROUND: Antibiotic resistance is a challenge in the management of infectious diseases and can cause substantial cost. Even without the onset of infection, measures must be taken, as patients colonized with multi-drug resistant (MDR) pathogens may transmit the pathogen. We aim to quantify the cost of community-acquired MDR colonizations using routine data from a German teaching hospital. METHODS: All 2006 cases of documented MDR colonization at hospital admission recorded from 2011 to 2014 are matched to 7917 unexposed controls with the same primary diagnosis. Cases with an onset MDR infection are excluded from the analysis. Routine data on costs per case is analysed for three groups of MDR bacteria: Methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococcus (VRE), and multidrug-resistant gram-negative bacteria (MDR-GN). Multivariate analyses are conducted to adjust for potential confounders. RESULTS: After controlling for main diagnosis group, age, sex, and Charlson Comorbidity Index, MDR colonization is associated with substantial additional costs from the healthcare perspective (€1480.9, 95%CI €1286.4–€1675.5). Heterogeneity between pathogens remains. Colonization with MDR-GN leads to the largest cost increase (€1966.0, 95%CI €1634.6–€2297.4), followed by MRSA with €1651.3 (95%CI €1279.1–€2023.6), and VRE with €879.2 (95%CI €604.1–€1154.2). At the same time, MDR-GN is associated with additional reimbursements of €887.8 (95%CI €722.1–€1053.6), i.e. costs associated with MDR-colonization exceed reimbursement. CONCLUSIONS: Even without the onset of invasive infection, documented MDR-colonization at hospital admission is associated with increased hospital costs, which are not fully covered within the German DRG-based hospital payment system. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12913-018-3549-0) contains supplementary material, which is available to authorized users. BioMed Central 2018-09-26 /pmc/articles/PMC6158851/ /pubmed/30257671 http://dx.doi.org/10.1186/s12913-018-3549-0 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Engler-Hüsch, Sabine
Heister, Thomas
Mutters, Nico T
Wolff, Jan
Kaier, Klaus
In-hospital costs of community-acquired colonization with multidrug-resistant organisms at a German teaching hospital
title In-hospital costs of community-acquired colonization with multidrug-resistant organisms at a German teaching hospital
title_full In-hospital costs of community-acquired colonization with multidrug-resistant organisms at a German teaching hospital
title_fullStr In-hospital costs of community-acquired colonization with multidrug-resistant organisms at a German teaching hospital
title_full_unstemmed In-hospital costs of community-acquired colonization with multidrug-resistant organisms at a German teaching hospital
title_short In-hospital costs of community-acquired colonization with multidrug-resistant organisms at a German teaching hospital
title_sort in-hospital costs of community-acquired colonization with multidrug-resistant organisms at a german teaching hospital
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158851/
https://www.ncbi.nlm.nih.gov/pubmed/30257671
http://dx.doi.org/10.1186/s12913-018-3549-0
work_keys_str_mv AT englerhuschsabine inhospitalcostsofcommunityacquiredcolonizationwithmultidrugresistantorganismsatagermanteachinghospital
AT heisterthomas inhospitalcostsofcommunityacquiredcolonizationwithmultidrugresistantorganismsatagermanteachinghospital
AT muttersnicot inhospitalcostsofcommunityacquiredcolonizationwithmultidrugresistantorganismsatagermanteachinghospital
AT wolffjan inhospitalcostsofcommunityacquiredcolonizationwithmultidrugresistantorganismsatagermanteachinghospital
AT kaierklaus inhospitalcostsofcommunityacquiredcolonizationwithmultidrugresistantorganismsatagermanteachinghospital